FDA approves MS drug Extavia
Novartis has received the FDA approval for its multiple sclerosis (MS) medicine Extavia. The drug has been approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging.
- The FDA approves Novartis’ high blood pressure drug
- FDA approves new formulation Vaprisol
- FDA approves Duramed’s LoSEASONIQUE(R) oral contraceptive
- FDA approves hGH needle-free injection by Teva
